ASCO GUIDELINES Bundle

Diffuse Astrocytic and Oligodendroglial Tumors in Adults

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475458

Contents of this Issue

Navigation

Page 4 of 7

Recommendation 2.7 ➤ In people with glioblastoma, IDH-wildtype, CNS WHO grade 4 with older age, poor performance status or with concerns about toxicity or prognosis, best supportive care alone, hypofractionated radiation therapy alone (for MGMT promotor unmethylated tumors) or temozolomide alone (for MGMT promotor methylated tumors) are reasonable options. See Clinical Interpretation for further explanation. (Weak recommendation; IC-L) Recommendation 2.8 ➤ No recommendation for or against any therapeutic strategy can be made for treatment of recurrent glioblastoma, IDH-wildtype, CNS WHO grade 4. (No recommendation; IC-L) • People with recurrent glioblastoma should be referred for participation in a clinical trial where possible. (Strong recommendation; IC-N-L). Recommendation 2.9 ➤ No recommendation for or against any therapeutic strategy can be made for treatment of diffuse midline glioma. (No recommendation; IC-L) • People with diffuse midline glioma should be referred for participation in a clinical trial when possible. (Strong recommendation; IC-N-L).

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Diffuse Astrocytic and Oligodendroglial Tumors in Adults